Temporal trends in mortality and causes of death in patients with incident atrial fibrillation: a nationwide register study from 2010 to 2018
Our study reiterates that mortality after diagnosis of AF has decreased. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score highlights the need to treat comorbidities as it strongly associates with patient 1-year survival after initial AF diagnosis.
Authors
- Konsta Teppo (ORCID: https://orcid.org/0000-0002-4460-0994)
- Pirjo Mustonen (ORCID: https://orcid.org/0000-0003-1319-0248)
- Juhani K.E. Airaksinen (ORCID: https://orcid.org/0000-0002-0193-568X)
- Birgitta Salmela (ORCID: https://orcid.org/0009-0008-6801-0690)
- Aapo L. Aro (ORCID: https://orcid.org/0000-0001-7030-6740)
- Olli Halminen (ORCID: https://orcid.org/0000-0001-9266-8435)
- Jukka Putaala A (ORCID: https://orcid.org/0000-0002-6630-6104)
- Elis Kouki (ORCID: https://orcid.org/0000-0002-5759-0916)
- Jari K. Haukka (ORCID: https://orcid.org/0000-0003-1450-6208)
- Mika Lehto (ORCID: https://orcid.org/0000-0002-8691-5142)
- Mika Linna
- Juha Hartikainen
Institutions
- University of Helsinki (FI)
- University of Turku (FI)
- University of Eastern Finland (FI)
- Helsinki University Hospital (FI)
- Jorvi Hospital (FI)
- Turku University Hospital (FI)
- Kuopio University Hospital (FI)
- Päijät-Hämeen Keskussairaala (FI)
- Aalto University (FI)
Publication Details
- Journal
- BMJ Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1136/bmjopen-2023-080836
- Citations
- 4
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Foundation for Cardiovascular Research
- Helsingin ja Uudenmaan Sairaanhoitopiiri
- Yrjö Jahnssonin Säätiö
- Aarne Koskelon Säätiö
- Novo Nordisk
- Sydäntutkimussäätiö
- Sigrid Juséliuksen Säätiö
- Business Finland